Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up

by Novella Pugliese, Marco Picardi, Roberta Della Pepa, Claudia Giordano, Francesco Muriano, Aldo Leone, Giuseppe Delle Cave, Alessandro D’Ambrosio, Violetta Marafioti, Maria Gabriella Rascato, Daniela Russo, Massimo Mascolo, Fabrizio Pane
Published 2021-04-01